MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ALKS stock logo

ALKS

Alkermes plc

$31.45
0.47
 (1.52%)
Exchange:  
Market Cap:   5.192B
Shares Outstanding:   16.531M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Richard F. Pops
Full Time Employees:  1800
Address: 
Connaught House
Dublin
4
IE
Website:  https://www.alkermes.com
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

🔒 You are currently logged out

Login

It’s free

View full analyst estimates

Earnings Call

🔒 You are currently logged out

Login

It’s free

Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Balance Sheet

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Cash Flow Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Analyst Estimates

(* All numbers are in thousands)

🔒 You are currently logged out

Login

It’s free

Current Key Metrics

🔒 You are currently logged out

Login

It’s free

Forward P/E Ratios

🔒 You are currently logged out

Login

It’s free

SWOT Analysis

🔒 You are currently logged out

Login

It’s free

At what price to buy it? –
Intrinsic Value Calculator


Calculate ALKS Intrinsic Value

🔒 You are currently logged out

Login

It’s free

See in Nexus

Relevant news

21-10-2025 12:41
ALKS vs. RGEN: Which Stock Is the Better Value Option?
20-10-2025 16:00
Alkermes to Report Third Quarter Financial Results on October 28, 2025
08-09-2025 03:15
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Investment Compounding Calculator
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read